SCHEMBL5651370

SCHEMBL5651370

CCOc1cc(C(=O)NCCCN(CC)CC)ccc1-c1nc2c(C)cccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 2/20 0.51
TSHR P16473 1/20 0.43
APLNR P35414 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
PIM1 P11309 1/20 0.42
GSK3A P49840 1/20 0.42
RPS6KA3 P51812 1/20 0.42
PRKCD Q05655 1/20 0.42
DYRK1A Q13627 1/20 0.42
PIM3 Q86V86 1/20 0.42
BRSK1 Q8TDC3 1/20 0.42
AURKB Q96GD4 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649720 0.92 TSHR (0.43) HPSETSHRPRMT5WDR77PRKD3
SCHEMBL5650407 0.89 APLNR (0.47) HPSETSHRAPLNRPRMT5WDR77
SCHEMBL5648785 0.89 HPSE (0.53) HPSEAPLNRHTTMAPTGAA
SCHEMBL5650993 0.87 HPSE (0.49) HPSETSHRAPLNRPRMT5WDR77
SCHEMBL5654556 0.86 PRMT5 (0.42) TSHRPRMT5WDR77HTTMAPT
SCHEMBL5652439 0.85 HPSE (0.44) HPSETSHRPRMT5WDR77HTT
SCHEMBL5653304 0.84 HDAC6 (0.47) HPSETSHRPRMT5WDR77HTT
SCHEMBL5648995 0.84 PRMT5 (0.49) TSHRPRMT5WDR77PRKD3PRKCG
SCHEMBL5652453 0.83 HTT (0.45) HPSETSHRPRMT5WDR77HTT
SCHEMBL5652463 0.83 HTT (0.45) HPSETSHRPRMT5WDR77HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235559-B1 Therapeutic quinazoline derivatives ASTRAZENECA AB (SE) 2007-06-26 US disclosed
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed
EP-1218355-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2002-07-03 EP disclosed
WO-2001021597-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HPSE 3728/4885TSHR 161/4885APLNR 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.